Michael Panzara

Michael Panzara

Chief Tech/Sci/R&D Officer at IMMUNIC, INC.

Net worth: - $ as of 30/06/2026

59 year
Health Technology
Consumer Services

Profile

Michael A. Panzara is currently Director at Cadenza Bio, Inc., Independent Director at LeonaBio, Inc. since 2022, and Chief Medical Officer at Immunic, Inc. starting in 2026.
Formerly, Dr. Panzara was Director at Wave Life Sciences UK Ltd. from 2018 to 2022, Chief Medical Officer & Head-Therapeutics at Wave Life Sciences Ltd. from 2020 to 2022, Chief Medical Officer at Neurvati Neurosciences, Inc. from 2022 to 2026, Head-Multiple Sclerosis & Neurology at Genzyme Corp.
from 2009 to 2016, and Chief Medical Officer-Neurology & Vice President at Biogen, Inc. from 2001 to 2009.
Education includes an undergraduate degree from the University of Pennsylvania in 1989, a doctorate from Stanford University School of Medicine in 1994, and a graduate degree from Harvard T.H.
Chan School of Public Health in 2002.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
23/06/2026 0 ( -.--% ) - $ 30/06/2026

Michael Panzara active positions

CompaniesPositionStart
LEONABIO, INC. Director/Board Member 18/03/2022
IMMUNIC, INC. Chief Tech/Sci/R&D Officer 24/04/2026

Former positions of Michael Panzara

CompaniesPositionEnd
Chief Tech/Sci/R&D Officer 01/03/2026
WAVE LIFE SCIENCES LTD. Chief Tech/Sci/R&D Officer 14/10/2022
Director/Board Member 01/01/2022
Corporate Officer/Principal 01/07/2016
BIOGEN INC. Corporate Officer/Principal 01/09/2009
See the detail of Michael Panzara's experience

Training of Michael Panzara

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

98

1st degree connections

10

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies10

Health Technology

Health Technology

Health Technology

Health Technology

Consumer Services

Consumer Services

Consumer Services

Health Technology

Health Technology

Health Technology

  1. Stock Market
  2. Insiders
  3. Michael Panzara